Collegium Announces $35M Accelerated Buyback Program, As Part Of The $150M Share Repurchase Program Authorized By Its Board Of Directors In January 2024
Collegium Announces $35M Accelerated Buyback Program, As Part Of The $150M Share Repurchase Program Authorized By Its Board Of Directors In January 2024
Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $35 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $115 million remaining under the program.
致力於改善嚴重疾病患者生活的領先多元化專業製藥公司Collegium Pharmaceutical, Inc.（納斯達克股票代碼：COLL）今天宣佈，它已與傑富瑞集團簽訂加速股票回購（“ASR”）協議，回購該公司3500萬美元的普通股。Collegium將執行ASR，這是其董事會於2024年1月批准的1.5億美元股票回購計劃的一部分。該ASR完成後，Collegium將在該計劃下剩餘1.15億美元。
譯文內容由第三人軟體翻譯。